Item 1.01 - Entry into a Material Definitive Agreement.
On March 13, 2015, ADMA Biologics, Inc. (“ADMA” or the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Raymond James & Associates, Inc. (“Raymond James”), as representative (the “Representative”) of the underwriters identified therein (the “Underwriters”), with respect to the sale by the Company of 1,225,000 shares, together with a 30-day option granted to the Underwriters to purchase up to an additional 183,750 shares to cover over-allotments, if any (collectively, the “Public Offering Shares”) of the Company's Common Stock, par value $0.0001 per share (“Common Stock”). The Public Offering Shares are being sold to the public at an offering price of $8.00 per share, less an underwriting discount of 6% payable by the Company (the “Offering”).
The Public Offering Shares will be issued pursuant to a final prospectus supplement filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “Securities Act”), in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-200638), which became effective on December 23, 2014. The Company expects to close the Offering on March 18, 2015, subject to the satisfaction of customary closing conditions as set forth in the Underwriting Agreement.
The Underwriting Agreement contains customary representations and warranties by the Company, and customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, lock-up and termination provisions.
The Underwriting Agreement has been attached hereto as an exhibit to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties in connection with the execution of the Underwriting Agreement.
The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits.
|
Exhibit Number
|
Description
|
| |
|
|
1.1
|
Underwriting Agreement, dated March 13, 2015 between the Company and Raymond James & Associates, Inc., as the representative of the underwriters
|
|
5.1
|
Opinion of Dentons US LLP
|
|
23.1
|
Consent of Dentons US LLP (included in its opinion filed as Exhibit 5.1 hereto)
|
|
99.1
|
Press Release announcing Pricing of the Offering, dated March 13, 2015
|